Physician profile
Kyle D Bartol
NPI 1669854295
$1,904.41
in general payments reported to CMS, 2019-2025
11 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $805 · 2023: $868 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676 · Travel and Lodging: $225 · Education: $73.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.53 |
| Travel and Lodging | $224.87 |
| Education | $73.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $424.91 | 2023 | |
| Abiomed | $282.16 | 2022 | |
| Medtronic, INC. | $242.53 | 2022-2023 | Onyx Frontier |
| Abbott Laboratories | $206.53 | 2022 | |
| W. L. Gore & Associates, INC. | $123.00 | 2022-2025 | Gore Cardioform Septal Occluder |
| Cardiovascular Systems INC. | $117.25 | 2022 | |
| Penumbra, INC. | $111.06 | 2023 | Indigo System |
| Cordis US Corp. | $102.06 | 2023 | Mynx Control |
| Cathworks, INC. | $84.12 | 2023 | Ffrangio |
| Chiesi USA, INC. | $72.00 | 2023 | Kengreal |
| Cardiva Medical, INC. | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Bartol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.